Trastuzumab deruxtecan shows durable activity in HER2-mutant non-small cell lung cancer

被引：0
|
作者：
O'Rourke, Kate
机构：
来源：
CANCER | 2022年 / 128卷 / 05期
关键词：
D O I：
10.1002/cncr.34102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：938 / 938
页数：1
相关论文
共 50 条
  • [21] Trastuzumab Deruxtecan in HER2-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC): Interim Results of DESTINY-Lung01
    Smit, E.
    Nakagawa, K.
    Nagasaka, M.
    Felip, E.
    Goto, Y.
    Li, B.
    Pacheco, J.
    Murakami, H.
    Barlesi, F.
    Saltos, A.
    Perol, M.
    Udagawa, H.
    Saxena, K.
    Shiga, R.
    Guevara, F.
    Acharyya, S.
    Shahidi, J.
    Planchard, D.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S173 - S173
  • [22] Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report
    Riudavets, Mariona
    Azarine, Arshid
    Smaali, Sondes
    Kim, Young-Wouk
    Montpreville, Vincent Thomas de
    Grecea, Alina Miruna
    Naltet, Charles
    Gazzah, Annas
    Planchard, David
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (12):
  • [23] Preclinical activity of BAY 2927088 in HER2 mutant non-small cell lung cancer
    Siegel, Franziska
    Karsli-Uzunbas, Gizem
    Kotynkova, Kristyna
    McVeigh, Quinn
    Siegel, Stephan
    Korr, Daniel
    Schulze, Volker
    Berger, Markus
    Beckmann, Georg
    Cherniack, Andrew
    Meyerson, Matthew
    Greulich, Heidi
    CANCER RESEARCH, 2023, 83 (07)
  • [24] Non-small cell Lung Cancer: Trastuzumab and Deruxtecan Compination has an anti-cancer effect
    Metzger, Leandra
    PNEUMOLOGIE, 2021, 75 (11): : 835 - 835
  • [25] Patritumab Deruxtecan Is Efficacious in EGFR-Mutant Non-Small Cell Lung Cancer
    Zhang, H.
    Yu, X.
    Ye, J.
    Li, H.
    Hu, J.
    Tan, Y.
    CANCER DISCOVERY, 2023, 13 (12) : 2501 - 2501
  • [26] Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer REPLY
    Li, Bob T.
    Smit, Egbert F.
    Janne, Pasi A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (18): : 1770 - 1771
  • [27] Trastuzumab Deruxtecan Monotherapy in Pretreated HER2-overexpressing Nonsquamous Non-Small Cell Lung Cancer: DESTINY-Lung03 Part 1
    Planchard, D.
    Kim, H. R.
    Suksombooncharoen, T.
    Li, R.
    Samol, J.
    Runglodvatana, Y.
    Lee, K. -Y.
    Chang, G. -C.
    Kowalski, D.
    Han, J. -Y.
    Saw, S.
    Huang, Y.
    Sookprasert, A.
    Nakajima, E.
    Alfon, J.
    Chang, Y. -T.
    Yang, J. C. -H.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S46 - S47
  • [28] The role of HER2/neu expression and trastuzumab in non-small cell lung cancer
    Hirsch, FR
    Langer, CJ
    SEMINARS IN ONCOLOGY, 2004, 31 (01) : 75 - 82
  • [29] Pyrotinib Combined with Apatinib for HER2-Mutant Non-Small Cell Lung Cancer: Interim Analysis from a Phase II Clinical Study
    Yang, G.
    Xu, H.
    Xu, F.
    Yang, L.
    Li, H.
    Zhang, S.
    Yang, Y.
    Ai, X.
    Wang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S672 - S673
  • [30] Spotlight on Trastuzumab Deruxtecan (DS-8201, T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
    Azar, Ibrahim
    Alkassis, Samer
    Fukui, Jami
    Alsawah, Fares
    Fedak, Kalub
    Al Hallak, Mohammed Najeeb
    Sukari, Ammar
    Nagasaka, Misako
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 103 - 114
12345